KIT mutations have been reported in 15%‐46% of adults patients with t(8;21) CBF‐AML.13, 15, 16, 17, 18KIT D816V mutations were reported in 4%‐28% and strongly associated with poorer DFS (6%‐48%).13, 16, 19, 20 In pediatric populations, KIT mutations clustered in exon 17 and exon 8 were identified in 20‐30% of the CBF‐AML patients,21, 22, 23 yet its effect on prognosis is not agreed upon.22, 24 A meta‐analysis indicated KIT mutation increased relapse risk (RR at 2 years 1.76 [95% CI: 1.45‐2.12]) and decreased OS 1.35 (95% CI: 1.09‐1.66).25 This evidence concerns the gene CEBPZ and acute myeloid leukemia.